ERBB2 and osteosarcoma: We choose disialogangliosides (GD2) and human epidermal growth factor receptor-2 (HER2) as candidate target antigens because of their high expression across a number of osteosarcoma cell lines and their proven safety in IgG-mediated treatment of neuroblastomas and breast cancers using IgG monoclonal antibodies, respectively.